From Our Blog
Here’s a Little of What We’ve Learned Over the Years!
The Rome V international diagnostic criteria for all disorders of gut-brain interaction, of which IBS is the most common, has been published in the May 2026 issue of the medical journal Gastroenterology, and presented publicly earlier this month to the gastroenterology professional community at…
April is IBS Awareness Month in many countries. During this month every year, increased and very needed attention is given to IBS and the experiences of those of us who live with it. Join IBS Impact, other affected people, families, friends, IBS and functional…
The International Foundation for Gastrointestinal Disorders (IFFGD) is currently recruiting young people ages 15-23 who have diagnosed GI disorders for volunteer positions on a new advisory committee focused on the specific GI education, research and advocacy needs of those in this age range. IFFGD…
Shawn Case, IBS Impact’s first webmaster, along with many other roles in the community of people with IBS beginning in the 1990s, recently passed away. Read a tribute from the IBS Impact founder here. In Memory of Shawn Eric Case, IBS Impact Founding Webmaster…
The IBS Network, the national charity for irritable bowel syndrome, registered in England and Wales since 1991, has recently announced on its social media that unfortunately, for financial reasons, it must close at the end of June 2025. It will be transitioning some of…
Alfasigma USA, Inc. the United States distributor of tegaserod, brand name Zelnorm, which is a prescription medication for some women with IBS with constipation (IBS-C), has announced that as of June 30, 2022, it is no longer providing this medication. Alfasigma’s press release states…
The American Journal of Gastroenterology has published the American College of Gastroenterology’s newly updated guidelines for the management of irritable bowel syndrome (IBS) in its December 2020 issue. Seven named authors from the fields of gastroenterology and gastrointestinal health psychology, represent five United States…
Beginning in 2007, the International Foundation for Gastrointestinal Disorders (IFFGD) began conducting a multi-year comprehensive survey of people with IBS, their experiences and unmet needs. This survey attracted a large number of responses internationally and its insights have been important contributions to IBS research,…
This past week, the U.S Food and Drug Administration (FDA) approved the sale and distribution of a new medication for irritable bowel syndrome with constipation (IBS-C), tenapanor, to be known by the brand name Ibsrela. Tenapanor, a 50 mg. daily oral medication is approved…
The U.S Food and Drug Administration (FDA) has approved marketing of the IB-Stim device, for use in adolescents, ages 11-18, with functional gastrointestinal pain related to irritable bowel syndrome (IBS). IB-Stim, developed by Innovative Health Solutions in Indiana, is a small nerve stimulator device…